CA2101245A1 - Dosage forms comprising polymers comprising different molecular weights - Google Patents

Dosage forms comprising polymers comprising different molecular weights

Info

Publication number
CA2101245A1
CA2101245A1 CA002101245A CA2101245A CA2101245A1 CA 2101245 A1 CA2101245 A1 CA 2101245A1 CA 002101245 A CA002101245 A CA 002101245A CA 2101245 A CA2101245 A CA 2101245A CA 2101245 A1 CA2101245 A1 CA 2101245A1
Authority
CA
Canada
Prior art keywords
polymers
dosage forms
molecular weights
different molecular
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002101245A
Other languages
French (fr)
Other versions
CA2101245C (en
Inventor
Jeri Dawn Wright
Brian L. Barclay
David R. Swanson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Jeri Dawn Wright
Brian L. Barclay
David R. Swanson
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jeri Dawn Wright, Brian L. Barclay, David R. Swanson, Alza Corporation filed Critical Jeri Dawn Wright
Publication of CA2101245A1 publication Critical patent/CA2101245A1/en
Application granted granted Critical
Publication of CA2101245C publication Critical patent/CA2101245C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

A dosage form (10)is disclosed comprising a wall (12) surrounding a compartment (IS), which comprises a first composi-tion (16) comprising a carboxymethylcellulose (17) and a second composition (20) comprising a higher molecular weight carbox-ymethylcellulose (21).The first composition comprises a dosage amount of drug (16) that delivers from the dosage form (10) at a controlled rate over time.
CA002101245A 1991-04-22 1992-04-22 Dosage forms comprising polymers comprising different molecular weights Expired - Fee Related CA2101245C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/688,807 US5208037A (en) 1991-04-22 1991-04-22 Dosage forms comprising polymers comprising different molecular weights
US688,807 1991-04-22
PCT/US1992/003294 WO1992018102A1 (en) 1991-04-22 1992-04-22 Dosage forms comprising polymers comprising different molecular weights

Publications (2)

Publication Number Publication Date
CA2101245A1 true CA2101245A1 (en) 1992-10-23
CA2101245C CA2101245C (en) 2002-06-25

Family

ID=24765867

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002101245A Expired - Fee Related CA2101245C (en) 1991-04-22 1992-04-22 Dosage forms comprising polymers comprising different molecular weights

Country Status (17)

Country Link
US (2) US5208037A (en)
EP (1) EP0581862B1 (en)
JP (1) JP2638303B2 (en)
KR (1) KR0158466B1 (en)
AT (1) ATE142481T1 (en)
AU (1) AU655827B2 (en)
CA (1) CA2101245C (en)
DE (1) DE69213729T2 (en)
ES (1) ES2092115T3 (en)
FI (1) FI110160B (en)
IE (1) IE921269A1 (en)
MX (1) MX9201813A (en)
NO (1) NO306976B1 (en)
NZ (1) NZ242419A (en)
PT (1) PT100417B (en)
WO (1) WO1992018102A1 (en)
ZA (1) ZA922907B (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
HUT75616A (en) * 1992-03-17 1997-05-28 Pfizer Method for prooucing porous delivery devices
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
ES2168610T3 (en) * 1996-03-12 2002-06-16 Alza Corp COMPOSITION AND GALENIC FORM CONTAINING AN OPIOID ANTAGONIST.
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
EP0946151B1 (en) * 1996-11-25 2006-05-10 Alza Corporation Ascending-dose dosage form
EP1782798A3 (en) 1996-11-25 2008-05-21 Alza Corporation Ascending-dose dosage form
ZA979605B (en) * 1996-11-25 1998-05-21 Alza Corp Ascending-dose dosage form.
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
GT199800127A (en) * 1997-08-29 2000-02-01 THERAPEUTIC COMBINATIONS.
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
JP2003518487A (en) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク Hydrogel-driven laminated drug formulation
WO2001056543A1 (en) 2000-02-04 2001-08-09 Alza Corporation Osmotically-driven fluid dispenser and coating composition
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US20040001886A1 (en) * 2001-10-17 2004-01-01 Dr. Reddy's Laboratories Limited Stabilized pharmaceutical formulations containing amlodipine maleate
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20100010336A1 (en) * 2002-02-07 2010-01-14 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including attention deficit hyperactivity disorder (adhd), autism, and schizophrenia
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
JP2005523269A (en) * 2002-02-07 2005-08-04 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ Carnitine in the treatment of senile depression
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US8894973B2 (en) * 2002-02-07 2014-11-25 Jay W. Pettegrew Method and system for differential diagnosis of chronic schizophrenia and chronic alcoholism
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
HUE038446T2 (en) 2002-09-20 2018-10-29 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20120077206A1 (en) 2003-07-12 2012-03-29 Accelr8 Technology Corporation Rapid Microbial Detection and Antimicrobial Susceptibility Testing
US7687239B2 (en) 2003-07-12 2010-03-30 Accelrs Technology Corporation Sensitive and rapid determination of antimicrobial susceptibility
EP2484346B1 (en) 2006-06-19 2017-02-22 Alpharma Pharmaceuticals LLC Pharmaceutical compositions
CN100563637C (en) * 2006-10-13 2009-12-02 北京红林制药有限公司 A kind of medicated core compositions of controlled release drug administration and controlled release preparation and preparation method thereof
CN100563638C (en) * 2006-10-24 2009-12-02 北京红林制药有限公司 Nifedipine controlled-release tablet and preparation method thereof
DK2200588T3 (en) 2007-09-25 2019-07-01 Solubest Ltd COMPOSITIONS CONCERNING LIPOFILE ACTIVE RELATIONS AND METHOD OF PRODUCTION THEREOF
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2012071220A1 (en) * 2010-11-23 2012-05-31 Transcept Pharmaceuticals, Inc. Compositions and methods for once-daily administration of a trilayer osmotic tablet
US10254204B2 (en) 2011-03-07 2019-04-09 Accelerate Diagnostics, Inc. Membrane-assisted purification
ES2551922T3 (en) 2011-03-07 2015-11-24 Accelerate Diagnostics, Inc. Rapid cell purification systems
US9677109B2 (en) 2013-03-15 2017-06-13 Accelerate Diagnostics, Inc. Rapid determination of microbial growth and antimicrobial susceptibility
WO2015085312A1 (en) 2013-12-06 2015-06-11 Durect Corporation Compositions comprising antioxidant, fluid dispensers, and methods involving the same
US10253355B2 (en) 2015-03-30 2019-04-09 Accelerate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing
US10023895B2 (en) 2015-03-30 2018-07-17 Accelerate Diagnostics, Inc. Instrument and system for rapid microogranism identification and antimicrobial agent susceptibility testing
EP3364955B1 (en) 2015-10-09 2022-04-20 RB Health (US) LLC Pharmaceutical formulation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
GB2140487B (en) * 1983-05-25 1987-03-11 Baker Ham & Co Ltd Improvements relating to penstocks
US4717566A (en) * 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
US4863456A (en) * 1986-04-30 1989-09-05 Alza Corporation Dosage form with improved delivery capability
US4743248A (en) * 1986-08-11 1988-05-10 Alza Corporation Dosage form for delivering acid sensitive beneficial agent
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US4950486A (en) * 1987-10-02 1990-08-21 Alza Corporation Dosage form for treating cardiovascular diseases
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
US4859470A (en) * 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
US4966769A (en) * 1988-06-02 1990-10-30 Alza Corporation Method for delivering dosage form for diltiazem
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US4948593A (en) * 1989-05-15 1990-08-14 Alza Corporation Osmotic dosage form comprising an estrogen and a progestogen
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation

Also Published As

Publication number Publication date
PT100417B (en) 1999-06-30
NO933728L (en) 1993-10-18
NZ242419A (en) 1994-07-26
AU1917392A (en) 1992-11-17
KR0158466B1 (en) 1998-12-01
ES2092115T3 (en) 1996-11-16
MX9201813A (en) 1992-10-01
PT100417A (en) 1993-08-31
US5326571A (en) 1994-07-05
EP0581862B1 (en) 1996-09-11
US5208037A (en) 1993-05-04
FI934653A0 (en) 1993-10-21
CA2101245C (en) 2002-06-25
ZA922907B (en) 1993-02-24
FI110160B (en) 2002-12-13
ATE142481T1 (en) 1996-09-15
NO306976B1 (en) 2000-01-24
JPH06506952A (en) 1994-08-04
AU655827B2 (en) 1995-01-12
EP0581862A1 (en) 1994-02-09
DE69213729D1 (en) 1996-10-17
JP2638303B2 (en) 1997-08-06
WO1992018102A1 (en) 1992-10-29
FI934653A (en) 1993-10-21
DE69213729T2 (en) 1997-01-30
IE921269A1 (en) 1992-11-04

Similar Documents

Publication Publication Date Title
CA2101245A1 (en) Dosage forms comprising polymers comprising different molecular weights
CA2228249A1 (en) Pain-alleviating drug composition and method for alleviating pain
CA2142126A1 (en) Inhalation powder containing antistatic agent
CA2213700A1 (en) Pharmaceutical composition for piperidinoalkanol compounds
BG102021A (en) Dosage inhaler for albuterol
WO1996040055A3 (en) Biological agent compositions
CA2326756A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
EP0575123A3 (en) Ethylene copolymer composition.
EP0598626A3 (en) Ethylene copolymer composition.
AU5278096A (en) Novel taxoids, preparation thereof and pharmaceutical compositions containing same
CA2078221A1 (en) Pharmaceutical compositions comprising taurolidine and/or taurultam
WO2001041737A3 (en) Solid oral dosage form
CA2127443A1 (en) Denture Stabilizing Compositions
AU2710892A (en) Cytotoxic bicyclo (7.3.1) tridec-4-ene-2,6-diyne compounds and process for the preparation thereof
IL107147A0 (en) Combined polymers or copolymers,their preparation and pharmaceutical compositions comprising them
AU5652296A (en) Novel taxoids, preparation thereof, and pharmaceutical compo sitions containing same
WO1999038532A3 (en) Methods for the prevention and treatment of fibrosis and sclerosis
CA2118030A1 (en) Drug for increasing the level of testosterone in the body
AU8147094A (en) Novel taxoids, their preparation and pharmaceutical compositions containing them
CA2169694A1 (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use as a medicament or diagnostic, and medicament containing them
CA2114859A1 (en) Cytotoxic and antiviral compound
CA2217122A1 (en) Medical composition for curing thrombocytopenia
EP0613907A3 (en) Controlled molecular weight reduction of polymers.
AU7642894A (en) Low friction, hydrophilic, biocompatible compositions
IL109866A (en) Crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine(+)L-hydrogentartrate its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed